Morgan Stanley analyst Daniel Duran raised the firm’s price target on Lionsgate Studios (LION) to $14 from $11 and keeps an Overweight rating on the shares. GenAI has the potential to commoditize content, while proven IP “has value but must be nurtured,” the analyst tells investors in a note on the media and entertainment group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LION:
- Lionsgate Studios price target raised to $15 from $12 at Benchmark
- Lionsgate Studios downgraded to Neutral from Buy at Citi
- Lionsgate Studios price target raised to $14 from $12 at Baird
- Lionsgate Extends CEO Contract with Performance-Based Equity Plan
- The AI Backlash, or, The Hollywood Revolution That Fizzled